-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
rapid -X- _ O
reversal -X- _ O
of -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
vitamin -X- _ O
K -X- _ O
antagonists -X- _ O
is -X- _ O
often -X- _ O
required -X- _ O
in -X- _ O
cases -X- _ O
of -X- _ O
emergency -X- _ O
surgery -X- _ O
and -X- _ O
life-threatening -X- _ O
bleeding -X- _ O
, -X- _ O
or -X- _ O
during -X- _ O
bleeding -X- _ O
associated -X- _ O
with -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
such -X- _ O
as -X- _ O
intracranial -X- _ O
haemorrhage. -X- _ O
Increasingly -X- _ O
, -X- _ O
four-factor -X- _ B-Intervention
prothrombin -X- _ I-Intervention
complex -X- _ I-Intervention
concentrates -X- _ I-Intervention
( -X- _ I-Intervention
PCCs -X- _ I-Intervention
) -X- _ I-Intervention
containing -X- _ O
high -X- _ O
and -X- _ O
well-balanced -X- _ O
concentrations -X- _ O
of -X- _ O
vitamin -X- _ O
K- -X- _ O
dependent -X- _ O
coagulation -X- _ O
factors -X- _ O
are -X- _ O
recommended -X- _ O
for -X- _ O
emergency -X- _ O
oral -X- _ O
anticoagulation -X- _ O
reversal. -X- _ O
Both -X- _ O
the -X- _ O
safety -X- _ O
and -X- _ O
efficacy -X- _ O
of -X- _ O
such -X- _ O
products -X- _ O
are -X- _ O
currently -X- _ O
in -X- _ O
focus -X- _ O
, -X- _ O
and -X- _ O
their -X- _ O
administration -X- _ O
is -X- _ O
now -X- _ O
expanding -X- _ O
into -X- _ O
the -X- _ O
critical -X- _ O
care -X- _ O
setting -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
life-threatening -X- _ B-Patient
bleeding -X- _ I-Patient
and -X- _ I-Patient
coagulopathy -X- _ I-Patient
resulting -X- _ O
either -X- _ O
perioperatively -X- _ O
or -X- _ O
in -X- _ O
cases -X- _ O
of -X- _ O
acute -X- _ O
trauma. -X- _ O
METHODS -X- _ O
: -X- _ O
After -X- _ O
15 -X- _ O
yr -X- _ O
of -X- _ O
clinical -X- _ O
use -X- _ O
, -X- _ O
findings -X- _ O
of -X- _ O
a -X- _ O
pharmacovigilance -X- _ O
report -X- _ O
( -X- _ O
February -X- _ O
1996–March -X- _ O
2012 -X- _ O
) -X- _ O
relating -X- _ O
to -X- _ O
the -X- _ O
four-factor -X- _ B-Intervention
PCC -X- _ I-Intervention
Beriplex -X- _ I-Intervention
P -X- _ I-Intervention
/ -X- _ I-Intervention
N -X- _ I-Intervention
( -X- _ O
CSL -X- _ O
Behring -X- _ O
, -X- _ O
Marburg -X- _ O
, -X- _ O
Germany -X- _ O
) -X- _ O
were -X- _ O
analysed -X- _ O
and -X- _ O
are -X- _ O
presented -X- _ O
here. -X- _ O
Furthermore -X- _ O
, -X- _ O
a -X- _ O
review -X- _ O
of -X- _ O
the -X- _ O
literature -X- _ O
with -X- _ O
regard -X- _ O
to -X- _ O
the -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
four-factor -X- _ B-Intervention
PCCs -X- _ I-Intervention
was -X- _ O
performed. -X- _ O
RESULTS -X- _ O
: -X- _ O
Since -X- _ O
receiving -X- _ O
marketing -X- _ O
authorization -X- _ O
( -X- _ O
February -X- _ O
21 -X- _ O
, -X- _ O
1996 -X- _ O
) -X- _ O
, -X- _ O
∼647 -X- _ O
250 -X- _ O
standard -X- _ O
applications -X- _ O
of -X- _ O
Beriplex -X- _ O
P -X- _ O
/ -X- _ O
N -X- _ O
have -X- _ O
taken -X- _ O
place. -X- _ O
During -X- _ O
this -X- _ O
time -X- _ O
, -X- _ O
21 -X- _ B-Outcome
thromboembolic -X- _ I-Outcome
events -X- _ I-Outcome
judged -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
possibly -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
Beriplex -X- _ I-Outcome
P -X- _ I-Outcome
/ -X- _ I-Outcome
N -X- _ I-Outcome
administration -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
reported -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
no -X- _ I-Outcome
incidences -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
transmission -X- _ I-Outcome
or -X- _ I-Outcome
heparin-induced -X- _ I-Outcome
thrombocytopenia -X- _ I-Outcome
were -X- _ I-Outcome
documented. -X- _ I-Outcome
The -X- _ I-Outcome
low -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
thromboembolic -X- _ I-Outcome
events -X- _ I-Outcome
reported -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
observation -X- _ I-Outcome
period -X- _ I-Outcome
( -X- _ I-Outcome
one -X- _ I-Outcome
in -X- _ I-Outcome
∼31 -X- _ I-Outcome
000 -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
in -X- _ I-Outcome
line -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
incidence -X- _ I-Outcome
observed -X- _ I-Outcome
with -X- _ I-Outcome
other -X- _ I-Outcome
four-factor -X- _ I-Outcome
PCCs. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ O
general -X- _ O
, -X- _ O
four-factor -X- _ O
PCCs -X- _ O
have -X- _ O
proven -X- _ O
to -X- _ O
be -X- _ O
well -X- _ O
tolerated -X- _ O
and -X- _ O
highly -X- _ O
effective -X- _ O
in -X- _ O
the -X- _ O
rapid -X- _ O
reversal -X- _ O
of -X- _ O
vitamin -X- _ O
K -X- _ O
antagonists -X- _ O
. -X- _ O

